Dan Becker
Biotech Investor at Access Biotechnology
New York, New York
Overview
Work Experience
Managing Director, Access Biotechnology
2019 - Current
Biopharma investing in private and public companies across therapeutic areas, modalities, and development stages. Representative private investments include Nimbus Therapeutics (Tyk2 subsidiary acq. by Takeda for up to $6 billion incl. $4 billion upfront), Hemab, Areteia Therapeutics, Perfuse Therapeutics, and Matchpoint Therapeutics www.accessbiotech.com
Access Industries is a privately held industrial group with long-term holdings worldwide.
Board Member
2025
Board Member
2022 - 2025
IPO May 2023 (NASDAQ: SLRN); merged with Alumis Inc, (NASDAQ: ALMS) in May 2025
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.
Raised $558,000,000.00 from Westlake Village BioPartners, Cowen Healthcare Investments, OrbiMed, Samsara BioCapital, Decheng Capital, Matrix Capital Management, venBio Partners, Marshall Wace, Access Biotechnology and Tybourne Capital Management.
Board Member
2021 - 2024
Co-founding investor; acquired by Novartis for up to $1.75 billion including $1 billion upfront
Mariana Oncology is a biotechnology research industry.
Raised $250,000,000.00 from RA Capital Management, Nextech Invest, Surveyor Capital, Atlas Ventures, Forbion Capital Partners, Deep Track Capital, Eli Lilly and Access Biotechnology.
Board Member
2019 - 2024
IPO May 2021 (NASDAQ: DAWN)
Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Raised $687,500,000.00 from Fairmount Funds Management, Braidwell, Deerfield, Wellington Management, Access Biotechnology and Frazier Healthcare Partners.
Board Member
2021 - 2023
Acquired by Novartis for up to $1 billion including $0.5 billion upfront
Board Member
2020 - 2021
IPO July 2020 (NASDAQ: PAND); Acquired by Merck for $1.85 billion April 2021
Board Member
2017 - 2020
IPO Sept. 2018 (NASDAQ: PRNB); Acquired by Sanofi for $3.7 billion Sept. 2020
Principia Biopharma is dedicated to bringing oral therapies to patients with significant unmet medical needs in immunology & oncology.
Raised $337,799,978.00 from Mission BioCapital.
Principal
2015 - 2019
New Leaf Venture Partners is a venture capital firm focused on investments in healthcare technology companies.
Principal
2009 - 2015
Core member of Health Care practice, with emphasis on pharma R&D and experience across multiple subsectors. Selected for Ambassador program, transferred to London office during 2012.
BCG Securities focuses on wealth management with high net worth individuals.